Roche’s Ocrevus shows efficacy against two forms of multiple sclerosis

Roche has announced new clinical data demonstrating the benefits its drug Ocrevus provides in the treatment of two forms of multiple sclerosis.

New analyses from three phase III studies have been presented at the annual congress of the European Committee for Treatment and Research in Multiple Sclerosis, showing the effectiveness of Ocrevus in treating relapsing and primary progressive multiple sclerosis.

It was shown that a 75 percent higher proportion of relapsing multiple sclerosis patients achieved NEDA (no evidence of disease activity) status with Ocrevus compared with an established alternative.

Meanwhile, a 47 percent higher proportion of primary progressive multiple sclerosis patients achieved NEP (no evidence of progression) status with Roche's drug compared to placebo.

Professor Gavin Giovannoni, chair of neurology at Barts and The London School of Medicine and Dentistry, said: "This new data suggests that ocrelizumab consistently impacts disease progression and has the potential to change how we approach treating both relapsing and primary progressive multiple sclerosis."

Ocrevus is currently being assessed for regulatory approval by the European Medicines Agency and the US Food and Drug Administration.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.